{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Neoplasm&page=3", "query": { "condition": "Gastric Neoplasm", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1089, "total_pages": 109, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Neoplasm&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Neoplasm&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T19:39:54.374Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Solid Tumors", "NSCLC", "Bladder Cancer", "HNSCC", "Renal Cancer", "Melanoma", "Anal Cancer", "Colorectal Cancer", "Cholangiocarcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "Continue PD-1/PD-L1 Inhibitors treatment", "type": "DRUG" }, { "name": "Discontinue PD-1/PD-L1-1 inhibitor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2019-11-15", "completion_date": "2025-11-07", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157985" }, { "nct_id": "NCT01794793", "title": "Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cushing's Disease", "Acromegaly", "Neuroendocrine Tumors", "Pituitary Tumors", "Ectopic ACTH Secreting (EAS) Tumors", "Dumping Syndrome", "Prostate Cancer", "Melanoma Negative for bRAF", "Melanoma Negative for nRAS" ], "interventions": [ { "name": "Pasireotide", "type": "DRUG" }, { "name": "Cabergoline", "type": "DRUG" }, { "name": "Pasireotide LAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RECORDATI GROUP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2013-06-10", "completion_date": "2023-07-25", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01794793" }, { "nct_id": "NCT01438385", "title": "Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ampullary Cancer", "Duodenal Cancer", "Bile Duct Cancer", "Bile Duct Disorders", "Gallstones", "Obstructive Jaundice", "Pancreatic Disorders (Noncancerous)", "Colorectal Cancer", "Esophageal Cancer", "Barrett's Esophagus", "Gastric Malignancies", "Pancreatic Cancer", "Pediatric Gastroenterology", "Cholangiocarcinoma", "Pancreatic Pseudocysts", "Acute and Chronic Pancreatitis", "Recurrent Pancreatitis", "Cholangitis", "Bile Leak", "Biliary Strictures", "Pancreatic Divisum", "Biliary and Pancreatic Stones", "Choledocholithiasis" ], "interventions": [ { "name": "Interventional Endoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12000, "start_date": "2011-07", "completion_date": "2017-12-30", "has_results": false, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01438385" }, { "nct_id": "NCT05215574", "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Breast Cancer", "Gastric Cancer", "Non-small Cell Lung Cancer", "Cervical Cancer", "Endocervical Cancer", "Squamous Cell Carcinoma of Head and Neck", "Bladder Urothelial Cancer", "Colorectal Carcinoma", "Esophageal Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Prostate Cancer", "Melanoma", "Mesothelioma", "Cholangiocarcinoma" ], "interventions": [ { "name": "NGM831", "type": "DRUG" }, { "name": "NGM831 plus pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-03-31", "completion_date": "2026-03", "has_results": false, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 9, "location_summary": "Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05215574" }, { "nct_id": "NCT07488676", "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "ASP546C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-05-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488676" }, { "nct_id": "NCT05462717", "title": "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "RMC-6291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2022-09-19", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 15, "location_summary": "Springdale, Arkansas • Orange, California • Sacramento, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462717" }, { "nct_id": "NCT03071757", "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2017-03-21", "completion_date": "2022-04-13", "has_results": false, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 10, "location_summary": "La Jolla, California • Sacramento, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071757" }, { "nct_id": "NCT00909402", "title": "A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stomach Neoplasms", "Esophageal Neoplasms" ], "interventions": [ { "name": "BMS-833923", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2009-11", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Houston, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00909402" }, { "nct_id": "NCT04609592", "title": "Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "Gallium 68 Dotatate", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "PET/CT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-03-17", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04609592" }, { "nct_id": "NCT04740164", "title": "A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bile Duct Carcinoma", "Gallbladder Carcinoma", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Endoscopic Retrograde Cholangiopancreatography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2021-02-24", "completion_date": "2023-05-04", "has_results": true, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-10-22T19:39:54.374Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740164" } ] }